Grifols (GIFLF) Non-Current Debt (2009 - 2025)
Grifols' (GIFLF) quarterly Non-Current Debt came in at $10.6 billion in Q4 2025, up 4.34% on a YoY basis from $10.1 billion in Q4 2024, and up 4.34% quarter-over-quarter from $10.1 billion in Q4 2024.
Analysis
Grifols (GIFLF) Non-Current Debt (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Non-Current Debt for 17 consecutive years, with $10.6 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt rose 4.34% year-over-year to $10.6 billion; the trailing twelve-month figure through Dec 2025 stood at $10.6 billion (up 4.34% YoY), and the FY2025 full-year result was $10.3 billion, up 1.27% from the prior year.
- Non-Current Debt grew to $10.6 billion in Q4 2025 per GIFLF's latest filing, from $10.1 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $10.8 billion in Q4 2023 and bottomed at $8.9 billion in Q4 2021.
- Historically, Non-Current Debt has averaged $10.1 billion across 5 years, with a median of $10.3 billion in 2022.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt grew 15.65% in 2022, then declined 6.05% in 2024.
- Over 5 years, Non-Current Debt stood at $8.9 billion in 2021, then increased by 15.65% to $10.3 billion in 2022, then grew by 5.03% to $10.8 billion in 2023, then decreased by 6.05% to $10.1 billion in 2024, then advanced by 4.34% to $10.6 billion in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $10.6 billion, $10.1 billion, and $10.8 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 10.58 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 10.58 Bn |
| Dec 31, 2024 | 10.14 Bn |
| Dec 31, 2023 | 10.80 Bn |
| Dec 31, 2022 | 10.28 Bn |
| Dec 31, 2021 | 8.89 Bn |
| Dec 31, 2020 | 7.87 Bn |
| Sep 30, 2020 | 7.86 Bn |
| Mar 31, 2020 | 7.58 Bn |
| Dec 31, 2019 | 7.58 Bn |
| Sep 30, 2019 | 7.68 Bn |
| Dec 31, 2018 | 6.96 Bn |
| Sep 30, 2018 | 7.11 Bn |
| Jun 30, 2018 | 7.19 Bn |
| Mar 31, 2018 | 8.43 Bn |
| Dec 31, 2017 | 6.95 Bn |
| Jun 30, 2017 | 6.64 Bn |
| Dec 31, 2016 | 5.09 Bn |
| Sep 30, 2016 | 5.01 Bn |
| Jun 30, 2016 | 5.10 Bn |
| Mar 31, 2016 | 4.87 Bn |